All In Biotech

Drug Trial Radar · NCT03687632

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

Last checked: Nov 19, 2026Latest source record: Aug 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Jun 10, 2019

Primary completion

Aug 18, 2020

Study completion Aug 25, 2020

Sponsor

Sponsor type
Industry
First posted
Sep 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

  • ST266Biological

    1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with complete healing of PED during 28 days of treatment startingTime frame: 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Price Vision Group

    Indianapolis, Indiana

  • Cincinnati Eye Institute

    Edgewood, Kentucky

  • University of Maryland

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Univesity of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of West Virginia

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.